a specialty pharmaceuticals company based in Sweden, has agreed to a product deal with the GlaxoSmithKline Group (GSK) on Relifex - an anti-inflammatory medicine used by patients suffering from rheumatoid arthritis and pain disorders.
According to the agreement Meda acquires the full exclusive rights to Relifex in a number of European markets including the UK, Netherlands, Spain, Sweden, Denmark, Norway, Finland and the Baltic countries.
Relifex competes in the market of the very newest selective COX-2 inhibitors and the NSAID (non-Steroidal Anti-inflammatory Drug) medications, indicated in the therapy of inflammation and pain.
Relifex is an established and well-documented product, which fits well into one of our therapeutic priorities, inflammation and pain.
This divestment of Relifex is part of our post merger priority setting and we are pleased to have concluded this agreement with Meda.